Molica S, Tucci L, Levato D, Docimo C
Divisione Ematologia, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.
Haematologica. 1997 May-Jun;82(3):286-90.
Recently published studies dealing with chronic lymphocytic leukemia (CLL) patients in early clinical stage reported that bone marrow (BM) biopsies and aspirates can be considered complementary methods of evaluating the extent of BM involvement. Consequently, we designed the present study to investigate the clinical and prognostic implications of BM biopsies and aspirates in a series of stage A CLL patients followed-up in a single center.
BM biopsy sections and aspirate smears obtained at the time of diagnosis from 102 CLL stage A patients were retrospectively evaluated. Results were correlated with clinical and hematological features as well as with survival and disease-progression risk.
Diffuse (D) BM histology was detected in 10 patients (9.8%) while 21 (20.5%) displayed lymphocyte infiltration (LI) > 80%. Twenty-six patients (25.4%) died with a 5- and 10-year survival probability of 85% and 50%, respectively. The survival of patients with D-BM histology was significantly shorter than that of patients with non-diffuse (non-D) histology (p < 0.05). Interestingly, when considering only CLL-related deaths (i.e. leukemia progression, infections) were considered, there was an increase in the statistical significance of BM histology (p = 0.01). There was no difference in life expectancy in cases with LI either using different cut-off levels (i.e. 70% and 80%) or excluding non-CLL related deaths. According to our experience, disease progression could only be predicted by BM histology (p = 0.008), while LI was not useful for forecasting progression to more advanced stages (p = NS).
In patients with early CLL, BM histology provides more reliable information regarding the clinical outcome of the disease than LI.
近期发表的关于早期临床阶段慢性淋巴细胞白血病(CLL)患者的研究报告称,骨髓(BM)活检和穿刺可被视为评估骨髓受累程度的互补方法。因此,我们设计了本研究,以调查在单一中心随访的一系列A期CLL患者中,骨髓活检和穿刺的临床及预后意义。
对102例A期CLL患者诊断时获取的骨髓活检切片和穿刺涂片进行回顾性评估。结果与临床和血液学特征以及生存和疾病进展风险相关。
10例患者(9.8%)检测到弥漫性(D)骨髓组织学表现,而21例(20.5%)显示淋巴细胞浸润(LI)>80%。26例患者(25.4%)死亡,5年和10年生存概率分别为85%和50%。弥漫性骨髓组织学表现患者的生存期明显短于非弥漫性(非D)组织学表现患者(p<0.05)。有趣的是,仅考虑CLL相关死亡(即白血病进展、感染)时,骨髓组织学的统计学显著性增加(p = 0.01)。无论使用不同的临界值水平(即70%和80%)还是排除非CLL相关死亡,LI病例的预期寿命均无差异。根据我们的经验,疾病进展只能通过骨髓组织学预测(p = 0.008),而LI对预测进展到更晚期无帮助(p = 无显著性差异)。
在早期CLL患者中,与LI相比,骨髓组织学能提供关于疾病临床结局更可靠的信息。